Invivyd, Inc. (NASDAQ:IVVD) Receives Consensus Rating of “Hold” from Analysts

Invivyd, Inc. (NASDAQ:IVVD) has been assigned a consensus recommendation of “Hold” from the six analysts that are currently covering the stock, Marketbeat reports. Two analysts have rated the stock with a sell recommendation and four have assigned a buy recommendation to the company. The average 1-year target price among brokers that have issued a report on the stock in the last year is $6.3875.

Several research analysts have recently weighed in on the stock. D. Boral Capital increased their price objective on shares of Invivyd from $1.00 to $2.00 and gave the stock a “buy” rating in a report on Monday, October 6th. Zacks Research lowered shares of Invivyd from a “hold” rating to a “strong sell” rating in a research report on Wednesday, October 15th. Cantor Fitzgerald assumed coverage on shares of Invivyd in a research note on Monday, October 6th. They set an “overweight” rating and a $10.00 price target on the stock. HC Wainwright boosted their price objective on shares of Invivyd from $5.00 to $10.00 and gave the company a “buy” rating in a research note on Friday, October 31st. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Invivyd in a research report on Friday, October 31st.

Invivyd Stock Performance

IVVD stock opened at $1.54 on Friday. The company has a 50 day moving average price of $1.47 and a two-hundred day moving average price of $1.00. The stock has a market capitalization of $330.19 million, a P/E ratio of -1.67 and a beta of 0.64. Invivyd has a one year low of $0.35 and a one year high of $2.74.

Invivyd (NASDAQ:IVVD) last posted its quarterly earnings data on Thursday, August 14th. The company reported ($0.12) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.04) by ($0.08). The business had revenue of $11.79 million for the quarter, compared to analyst estimates of $23.16 million. Invivyd had a negative return on equity of 177.89% and a negative net margin of 238.33%. Research analysts forecast that Invivyd will post -1.64 earnings per share for the current fiscal year.

Insider Activity at Invivyd

In other news, insider Jill Andersen sold 49,402 shares of Invivyd stock in a transaction dated Tuesday, August 19th. The stock was sold at an average price of $0.57, for a total value of $28,159.14. Following the transaction, the insider directly owned 84,446 shares of the company’s stock, valued at $48,134.22. The trade was a 36.91% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. In the last quarter, insiders sold 277,654 shares of company stock valued at $167,215. Company insiders own 25.40% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. AQR Capital Management LLC grew its stake in Invivyd by 2,051.0% during the 1st quarter. AQR Capital Management LLC now owns 410,711 shares of the company’s stock valued at $249,000 after purchasing an additional 391,617 shares in the last quarter. Marshall Wace LLP acquired a new stake in shares of Invivyd during the second quarter worth approximately $158,000. Jane Street Group LLC bought a new stake in shares of Invivyd in the second quarter worth $147,000. XTX Topco Ltd acquired a new stake in Invivyd in the first quarter valued at $66,000. Finally, Nuveen LLC bought a new position in Invivyd during the 1st quarter valued at $65,000. 70.36% of the stock is owned by institutional investors and hedge funds.

About Invivyd

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.